A veteran biotech CEO argues that true accomplishment lies in assembling and empowering great teams, not claiming personal credit for milestones like drug approvals. He asserts that any leader who needs personal credit for collective achievements cannot be truly effective.
The advent of SSRIs was a major innovation that moved depression treatment into primary care and reduced stigma. However, this shift had a downside: physicians became less familiar with older, more cumbersome but potent drugs like MAOIs and lithium, narrowing the therapeutic arsenal for tough cases.
While companies fear losing to competitors, a bigger deterrent for head-to-head trials is the absence of a clear regulatory pathway to use favorable data (e.g., faster onset) for label claims. This removes a key commercial incentive for running these informative but risky studies.
Venture capitalists analyze risk and probability to make investment decisions, similar to a coach picking a team. In contrast, company operators are actively "on the playing field," designing programs and strategies to manage and overcome those same risks. It's a mindset shift from assessment to execution.
For CNS diseases, where animal models are notoriously unreliable predictors of efficacy, the most pragmatic R&D model is to quickly move promising new chemical entities into human trials. The focus shifts from extensive preclinical validation to early biological experimentation in humans for proof-of-concept.
The core innovation of psychedelics isn't just the mechanism but the treatment paradigm. By offering a rapid, acute treatment that doesn't require chronic medication, they could allow patients to get better and return to their lives, avoiding long-term entanglement with the mental health system and reducing stigma.
Tortugas Neuroscience's startup strategy focuses on in-licensing new chemical entities that have already cleared Phase 1, bypassing early toxicity and IND risks. Their criteria demand that each asset be extensible to multiple indications within CNS, creating operating leverage and maximizing the chances of success.
Acquiring a Phase 1-complete drug is only the first step. Tortugas Neuroscience creates value by redirecting these assets into novel indications. They pivoted a neurosteroid toward tinnitus after seeing compelling external data, targeting an unmet need where the drug's mechanism could treat the entire syndrome.